Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

NSF report details increase in business research and development

By Drug Discovery Trends Editor | September 20, 2013

According to a recent study published by the National Science Foundation (NSF), businesses spent more on research and development (R&D) in 2011 than they did in 2010.

Companies spent $294 billion on R&D performed in the United States during 2011, compared with $279 billion during 2010. Data are from the Business and R&D and Innovation Survey (BRDIS), which is co-sponsored by NSF and the U.S. Census Bureau.

BRDIS revealed that during 2011, companies in manufacturing industries performed $201 billion, or 68%, of domestic R&D. Companies in nonmanufacturing industries performed $93 billion of domestic R&D. For both types of industries, most of the funding came from the companies’ own funds, about 81%.

The U.S. federal government was the chief source of outside funding for R&D across all industries. Of the $55 billion paid for by others, the federal government contributed $31 billion. The majority of this government funding, $26 billion, came from the Department of Defense.

U.S. companies that performed or funded R&D reported domestic net sales of $9 trillion in 2011, according to BRDIS. Manufacturing industries with high levels of R&D intensity in 2011 were pharmaceuticals and medicines, aerospace products and parts, and computer and electronic products.

Business R&D Performance in the United States Increased in 2011

Source: National Science Foundation


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE